Can-Fite BioPharma (CANF) has released an update.
Can-Fite BioPharma has reported positive treatment outcomes using Namodenoson in a patient with decompensated liver cirrhosis under compassionate use at Soroka Medical Center in Israel. With a focus on addressing oncological and inflammatory diseases, Can-Fite’s Namodenoson is also undergoing Phase III and IIb clinical trials for advanced liver cancer and MASH, respectively. The improvement in liver function observed in the treated patient highlights the potential of Namodenoson as a significant therapeutic option in the growing liver cirrhosis treatment market.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
